AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06559280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: During the operation, 0.25mg/kg esketamine was induced, and 1mg/kg esketamine was added to the postoperative analgesia pump
Study NCT06547294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osprey IV
Description: Utilization of novel needle over catheter commercial insertion device
Study NCT06547294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Historical Controls
Description: Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
Study NCT05562778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
Study NCT04905082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT04905082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: View HOPE-Genomics tool after genomic test results are available
Study NCT06028529 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exoskeleton
Description: lightweight ground exoskeleton
Study NCT04905082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: View HOPE-Genomics before sequencing results are available
Study NCT04905082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genomic Profile
Description: Receive genomics test results
Study NCT04784871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5waysA Intervention
Description: Web-based 10 week intervention, encouraging participants engaging in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
Study NCT04784871 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 5waysA Active wait-list control
Description: Writing activity log in the waiting time. Then, after five months and the writing of activity log, the participants get the web-based intervention and SMS massages, which encourage the participants to engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
Study NCT04909034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-20
Description: Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
Study NCT04909034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution without active ingredients
Study NCT04784871 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 5waysA Inactive wait-list control
Description: No activity while the participants wait. After five months of waiting, the participants get the web-based intervention and SMS messages, which encourage participants engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
Study NCT06233942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C9074
Description: administered by intravenous infusion
Study NCT06233942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered by intravenous infusion
Study NCT04905082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04905082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06157268 — intervention group
Intervention type: OTHER
Intervention: Natural history and non therapeutical therapy
Description: This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation.
Study NCT05766553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality pod
Description: The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.
Study NCT05766553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patches and chewing gum
Description: Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.
Study NCT06360887 — intervention group
Intervention type: PROCEDURE
Intervention: Conservative
Description: Conservative treatment
Study NCT06360887 — intervention group
Intervention type: PROCEDURE
Intervention: ORIF
Description: Open surgery
Study NCT06360887 — intervention group
Intervention type: PROCEDURE
Intervention: CRPP
Description: Minimal invasive surgery
Study NCT05784740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week precision exercise training
Description: The 12-week exercise intervention will consist of both aerobic and strength exercise training performed 3x per week using an individualized and nonlinear periodized approach.
Study NCT05255614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality Simulator
Description: LapSim is a device designed by Surgical Science Device \& software at Swedan
Study NCT05255614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic trainer:
Description: Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
Study NCT06318962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aviva
Description: Digital phone app for BCBT
Study NCT05563480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
Description: TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study NCT05563480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
Description: Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study NCT05563480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection; Penpulimab injection
Description: TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study NCT01539265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin
Study NCT01539265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05372315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: (dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
Study NCT06136039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Sarcopenia)
Description: Same as standard treatment
Study NCT05853627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory reactivation procedures
Description: In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
Study NCT05853627 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory reactivation procedures
Description: In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
Study NCT05853627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
Study NCT05853627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
Study NCT05632562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
Description: High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
Study NCT05783258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery with CAF+tSCTG
Description: Coronally advanced flap and subepithelial connective tissue graft harvested from the maxillary tuberosity area.
Study NCT05783258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery with CAF+L-PRF
Description: Coronally advanced flap and L-PRF membranes
Study NCT06525220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petosemtamab
Description: MCLA-158
Study NCT06525220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Humanized Antibody
Study NCT06525220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized Antibody
Study NCT06251479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral 1
Description: verbal and non verbal tasks
Study NCT06251479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral 2
Description: verbal and non verbal tasks with other partecipants
Study NCT05773040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JV-213
Description: Given by (IV) vein
Study NCT05773040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Given by IV (vein)
Study NCT05086172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultrabrief Behavioral Activation
Description: The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
Study NCT05775575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3909 tablets
Description: TQB3909 is an inhibitor targeting BCL-2 protein
Study NCT06136039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm II(Normal)
Description: Same as standard treatment
Study NCT06251479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromodulation 1
Description: registration with neurophysiological tecniques during verbal and non verbal tasks
Study NCT06251479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromodulation 2
Description: registration with neurophysiological tecniques during verbal and non verbal tasks with other partecipants
Study NCT05675605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-1091
Description: TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
Study NCT04231643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: one-time oral administration of 5 mg dronabinol
Study NCT04231643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: one-time oral administration of 5 mg dronabinol
Study NCT04231643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: one-time oral administration of 600 mg Epidiolex
Study NCT04231643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex
Description: one-time oral administration of 600 mg Epidiolex
Study NCT04231643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: one-time oral administration of placebo
Study NCT04231643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: one-time oral administration of placebo
Study NCT05249855 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological measurement
Description: Psychological assessment
Study NCT04807868 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of care liver biopsy
Description: Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
Study NCT04807868 — intervention group
Intervention type: OTHER
Intervention: Fibroscan
Description: A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
Study NCT05537363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
Study NCT05537363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training
Description: Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
Study NCT05537363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility training
Description: The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
Study NCT06003933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 10 ml of 0.25% bupivacaine on each side of cervical region at C5
Study NCT06003933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 10ml xylocaine on each side of cervical region at C5
Study NCT06003933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.
Study NCT06003933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
Study NCT05767905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment A
Description: A single dose of PF-06821497 administered under fasting conditions.
Study NCT05767905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment B
Description: A single dose of PF-06821497 administered under fasting conditions.
Study NCT05767905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment C
Description: A single dose of PF-06821497 administered under fasting conditions.
Study NCT05767905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment D
Description: A single dose of PF-06821497 administered under fasting conditions.
Study NCT04807868 — intervention group
Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Blood and urine will be collected.
Study NCT05767905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment E
Description: A single dose of PF-06821497 administered after low fat meal
Study NCT05001555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Vitamin B
Description: 1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
Study NCT05001555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: 1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
Study NCT05767905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497 Treatment F
Description: A single dose of PF-06821497 administered after high fat meal.
Study NCT04180969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yohimbine + hydrocortisone
Description: yohimbine 54mg + hydrocortisone 20mg oral
Study NCT04180969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medial prefrontal cortex rTMS
Description: 1 Hz mPFC rTMS
Study NCT04180969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: placebo stressor
Study NCT04180969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo stressor
Study NCT04180969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham rTMS
Description: sham mPFC rTMS
Study NCT04180969 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: sham mPFC rTMS
Study NCT04946708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program (virtual/remote)
Description: Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
Study NCT04702685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic for injection
Study NCT04702685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bandage will be placed in the presumed injection site while patients in under general anesthesia
Study NCT05277402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG116
Description: IV infusion